✦ LIBER ✦

Therapy of hepatitis C: Cost-effectiveness analysis

✍ Scribed by R S Koff

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 113 KB
Volume: 26
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.510260726

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of hematologic growth

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

✍ Richard A. Del Rio; Anthony B. Post; Mendel E. Singer 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB 👁 1 views

Cost-effectiveness analysis of hepatitis

Cost-effectiveness analysis of hepatitis A vaccination strategies for adults

✍ J. Barry O'Connor; Thomas F. Imperiale; Mendel E. Singer 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

Our objective in this study was to determine the costeffectiveness of hepatitis A vaccination strategies in healthy adults in the United States. We constructed a decision model simulating costs and health consequences for otherwise healthy adults with respect to hepatitis A prevention. Three strateg

Bayesian cost-effectiveness analysis wit

Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane

✍ Miguel A. Negrín; Francisco J. Vázquez-Polo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB 👁 1 views

Cost-effectiveness analysis (CEA) compares the costs and outcomes of two or more technologies. However, there is no consensus about which measure of effectiveness should be used in each analysis. Clinical researchers have to select an appropriate outcome for their purpose, and this choice can have d

A cost-effectiveness analysis of RA biol

A cost-effectiveness analysis of RA biologics

📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB 👁 2 views

Cost-effectiveness of hepatitis C virus

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

✍ Natasha K. Martin; Peter Vickerman; Alec Miners; Graham R. Foster; Sharon J. Hut 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB 👁 1 views

Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a 1 ribavirin) has been shown to be costeffective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment

Cost-effectiveness analysis of the Lyme

Cost-effectiveness analysis of the Lyme disease vaccine

✍ Elizabeth C. Hsia; James B. Chung; J. Sanford Schwartz; Daniel A. Albert 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views